ANNOTATED BIBLIOGRAPHY

Books
1) Christopher P. Cannon .Management of Acute Coronary Syndromes, Vol. 1, edition-2, Springer-Verlag: New York, 1998 In this second edition of his highly acclaimed book, Christopher P. Cannon, MD, and a team of preeminent clinical investigators have thoroughly revised and expanded every chapter to reflect the recent explosion of clinical trials on the management of acute coronary syndromes (ACS). This includes: the newer tests, such as C reactive protein; a multimarker approach to diagnosis and risk stratification; new antiplatelet agents; and combinations of thrombolytic-antithrombotic regimens. Also discussed are the latest developments in interventional cardiology, the use of cost-effectiveness in clinical trials to choose appropriate therapies, and the employment of critical pathways analysis to improve compliance with evidence-based medicine and guideline recommendations. This book was found in the Bombay hospital library, new marine lines, Mumbai-20

2) Gerald C. Timmis. Thrombolytic Therapy. Edition-1, Futura Publishing Company: New York. 1999 The book covers the evolution of thrombolytic therapy for acute myocardial infarction in the 1980s and early 1900s, at a time when this therapy became the standard of care. The initial chapters are devoted to the development of intracoronary infusion of streptokinase. They provide a very detailed, almost case by case, description. The subsequent chapters by the early European and American consortiums of investigators of intravenous thrombolysis are written more broadly. These chapters are a "must read" for everyone involved with thrombolytic therapy of acute myocardial infarction. The last few chapters are a very informative description of the development of new thrombolytic agents. This book was found in the Bombay hospital library, new marine lines, Mumbai-20

JOURNAL 1) American Heart Journal. 8703(12)00064-6.Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and nonST elevation myocardial infarction American Heart Journal has been a trusted resource for cardiologists and general practice physicians for more than 80 years. The Journal focuses its content to respond to the information needs of the cardiology community. In addition to publishing results of

important clinical investigations, the Journal addresses such topics as cost-effectiveness, design of clinical trials, reports of negative clinical trials, and the changing organization of medical care. aimed to study the comparative safety and effectiveness of various antithrombotic treatment strategies among older adults with nonST elevation myocardial infarction (NSTEMI) and atrial fibrillation (AF).

Articles 1) Toth PP, McCullough PA, Wegner MS, Colley KJ. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3): pg 425-38. This review summarizes the large body of basic scientific and clinical research supporting the conclusion that inflammation plays a significant role in atherogenesis along the entire continuum of its progression Inflammation adversely impacts intravascular lipid handling and metabolism, and because Lp-PLA2 potentiates intravascular inflammation and atherosclerosis, many epidemiologic studies support the utility of Lp-PLA2 measurements for estimating and further refining cardiovascular disease risk. Also reviewed is a promising drug therapy in development that inhibits Lp-PLA2; darapladib inhibits Lp-PLA2 and reduces the progression of the necrotic core volume of coronary artery athermanous plaque.

2) Helft G, Worthley SG, Zaman AG, Samama MM, Badimon JJ. Thrombolysis and adjunctive therapies in acute myocardial infarction. Haemostasis 2000; 30:pg.159167 The authors have highlighted that thrombolysis and percutaneous transluminal angioplasty represent the cornerstone of the pharmacologic treatment of and the interventional approach to patients with myocardial infarction (MI). They are very effective. However, they are hampered by some critical limitations. Therefore, alternatives to standard thrombolytic therapy have been developed. Platelet glycoprotein (GP) IIb/IIIa blockade is under investigation and seems very attractive. This review focuses on the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to the thrombolytic treatment of patients with acute MI. This journal was found in the Bombay hospital library, new marine lines, Mumbai-20